# Omada Health, Inc.: financial statements, quarterly

OMDA · Nasdaq · CIK 1611115 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/omda.md) · [Financials](/companies/omda/financials.md) · [Filings](/companies/omda/filings.md) · [Insiders](/companies/omda/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/omda/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | [41.2](/filings/0001611115-25-000017.md) | [45.5](/filings/0001628280-25-050622.md) | [48.0 d](/filings/0001628280-26-015637.md) | [55.0](/filings/0001628280-26-032875.md) | [61.4](/filings/0001628280-26-054840.md) | [68.0](/filings/0001628280-25-050622.md) | [75.8 d](/filings/0001628280-26-015637.md) | [78.0](/filings/0001628280-26-032875.md) | [87.8](/filings/0001628280-26-054840.md) |
| Cost of revenue | $m | not reported | [16.4](/filings/0001611115-25-000017.md) | [17.0](/filings/0001628280-25-050622.md) | [15.8 d](/filings/0001628280-26-015637.md) | [23.1](/filings/0001628280-26-032875.md) | [21.1](/filings/0001628280-26-054840.md) | [23.0](/filings/0001628280-25-050622.md) | [22.2 d](/filings/0001628280-26-015637.md) | [29.4](/filings/0001628280-26-032875.md) | [24.0](/filings/0001628280-26-054840.md) |
| Gross profit | $m | not reported | [24.8](/filings/0001611115-25-000017.md) | [28.6](/filings/0001628280-25-050622.md) | [32.1 d](/filings/0001628280-26-015637.md) | [31.9](/filings/0001628280-26-032875.md) | [40.3](/filings/0001628280-26-054840.md) | [45.1](/filings/0001628280-25-050622.md) | [53.7 d](/filings/0001628280-26-015637.md) | [48.7](/filings/0001628280-26-032875.md) | [63.8](/filings/0001628280-26-054840.md) |
| Research and development | $m | not reported | [9.0](/filings/0001611115-25-000017.md) | [8.9](/filings/0001628280-25-050622.md) | [9.2 d](/filings/0001628280-26-015637.md) | [8.8](/filings/0001628280-26-032875.md) | [10.0](/filings/0001628280-26-054840.md) | [10.3](/filings/0001628280-25-050622.md) | [11.6 d](/filings/0001628280-26-015637.md) | [12.7](/filings/0001628280-26-032875.md) | [14.6](/filings/0001628280-26-054840.md) |
| Operating income | $m | not reported | [(10.0)](/filings/0001611115-25-000017.md) | [(8.5)](/filings/0001628280-25-050622.md) | [(7.1) d](/filings/0001628280-26-015637.md) | [(8.4)](/filings/0001628280-26-032875.md) | [(4.3)](/filings/0001628280-26-054840.md) | [(2.5)](/filings/0001628280-25-050622.md) | [3.3 d](/filings/0001628280-26-015637.md) | [(4.8)](/filings/0001628280-26-032875.md) | [3.5](/filings/0001628280-26-054840.md) |
| Interest expense | $m | not reported | [1.1](/filings/0001611115-25-000017.md) | [1.1](/filings/0001628280-25-050622.md) | [1.1 d](/filings/0001628280-26-015637.md) | [1.1](/filings/0001628280-26-032875.md) | [1.1](/filings/0001628280-26-054840.md) | [0.4](/filings/0001628280-25-050622.md) | [0.0 d](/filings/0001628280-26-015637.md) | [0.0](/filings/0001628280-26-032875.md) | [0.0](/filings/0001628280-26-054840.md) |
| Income tax | $m | not reported | [0.0](/filings/0001611115-25-000017.md) | [0.0](/filings/0001628280-25-050622.md) | [0.0 d](/filings/0001628280-26-015637.md) | [0.0](/filings/0001628280-26-032875.md) | [0.0](/filings/0001628280-26-054840.md) | [0.0](/filings/0001628280-25-050622.md) | [0.0 d](/filings/0001628280-26-015637.md) | [0.0](/filings/0001628280-26-032875.md) | [0.0](/filings/0001628280-26-054840.md) |
| Net income | $m | [(19.0)](/filings/0001628280-25-050622.md) | [(10.7)](/filings/0001628280-25-050622.md) | [(9.2)](/filings/0001628280-25-050622.md) | [(8.3) d](/filings/0001628280-26-015637.md) | [(9.4)](/filings/0001628280-26-054840.md) | [(5.3)](/filings/0001628280-26-054840.md) | [(3.2)](/filings/0001628280-25-050622.md) | [5.2 d](/filings/0001628280-26-015637.md) | [(3.0)](/filings/0001628280-26-054840.md) | [5.3](/filings/0001628280-26-054840.md) |
| Diluted EPS | $ per share | not reported | [(1.40)](/filings/0001611115-25-000017.md) | [(1.18)](/filings/0001628280-25-050622.md) | not reported | [(1.15)](/filings/0001628280-26-032875.md) | [(0.24)](/filings/0001628280-26-054840.md) | [(0.06)](/filings/0001628280-25-050622.md) | not reported | [(0.05)](/filings/0001628280-26-032875.md) | [0.08](/filings/0001628280-26-054840.md) |
| Basic EPS | $ per share | not reported | [(1.40)](/filings/0001611115-25-000017.md) | [(1.18)](/filings/0001628280-25-050622.md) | not reported | [(1.15)](/filings/0001628280-26-032875.md) | [(0.24)](/filings/0001628280-26-054840.md) | [(0.06)](/filings/0001628280-25-050622.md) | not reported | [(0.05)](/filings/0001628280-26-032875.md) | [0.09](/filings/0001628280-26-054840.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2022-12-31) | period not labelled (2023-12-31) | period not labelled (2024-03-31) | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | not reported | not reported | not reported | [76.4](/filings/0001628280-26-015637.md) | not reported | [223](/filings/0001611115-25-000017.md) | [199](/filings/0001628280-25-050622.md) | [222](/filings/0001628280-26-054840.md) | [212](/filings/0001628280-26-032875.md) | [222](/filings/0001628280-26-054840.md) |
| Current assets | $m | not reported | not reported | not reported | not reported | not reported | [113](/filings/0001628280-26-015637.md) | not reported | [271](/filings/0001611115-25-000017.md) | [255](/filings/0001628280-25-050622.md) | [273](/filings/0001628280-26-054840.md) | [269](/filings/0001628280-26-032875.md) | [295](/filings/0001628280-26-054840.md) |
| Total assets | $m | not reported | not reported | not reported | not reported | not reported | [151](/filings/0001628280-26-015637.md) | not reported | [303](/filings/0001611115-25-000017.md) | [287](/filings/0001628280-25-050622.md) | [305](/filings/0001628280-26-054840.md) | [303](/filings/0001628280-26-032875.md) | [328](/filings/0001628280-26-054840.md) |
| Current liabilities | $m | not reported | not reported | not reported | not reported | not reported | [54.0](/filings/0001628280-26-015637.md) | not reported | [58.0](/filings/0001611115-25-000017.md) | [70.1](/filings/0001628280-25-050622.md) | [75.7](/filings/0001628280-26-054840.md) | [68.7](/filings/0001628280-26-032875.md) | [75.5](/filings/0001628280-26-054840.md) |
| Total liabilities | $m | not reported | not reported | not reported | not reported | not reported | [86.3](/filings/0001628280-26-015637.md) | not reported | [88.8](/filings/0001611115-25-000017.md) | [70.1](/filings/0001628280-25-050622.md) | [75.7](/filings/0001628280-26-054840.md) | [68.7](/filings/0001628280-26-032875.md) | [75.5](/filings/0001628280-26-054840.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | [29.8](/filings/0001628280-26-015637.md) | not reported | [30.0](/filings/0001611115-25-000017.md) | [0.0](/filings/0001628280-25-050622.md) | [0.0](/filings/0001628280-26-015637.md) | not reported | not reported |
| Shareholders' equity | $m | [(293)](/filings/0001628280-26-015637.md) | [(350)](/filings/0001628280-26-015637.md) | [(365)](/filings/0001628280-25-050622.md) | [(373)](/filings/0001628280-25-050622.md) | [(380)](/filings/0001628280-25-050622.md) | [(384)](/filings/0001628280-26-054840.md) | [(390)](/filings/0001628280-26-054840.md) | [214](/filings/0001628280-26-054840.md) | [217](/filings/0001628280-25-050622.md) | [230](/filings/0001628280-26-054840.md) | [234](/filings/0001628280-26-054840.md) | [253](/filings/0001628280-26-054840.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebt
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | period not labelled (2024-09-30) | period not labelled (2024-12-31) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [1.1 d](/filings/0001628280-25-050622.md) | [(6.5) d](/filings/0001628280-26-015637.md) | [(16.1)](/filings/0001628280-26-032875.md) | [2.9 d](/filings/0001628280-26-054840.md) | [10.1 d](/filings/0001628280-25-050622.md) | [21.4 d](/filings/0001628280-26-015637.md) | [(11.8)](/filings/0001628280-26-032875.md) | [4.0 d](/filings/0001628280-26-054840.md) |
| Capital expenditure | $m | [0.1 d](/filings/0001628280-25-050622.md) | [0.2 d](/filings/0001628280-26-015637.md) | [0.3](/filings/0001628280-26-032875.md) | [0.3 d](/filings/0001628280-26-054840.md) | [0.5 d](/filings/0001628280-25-050622.md) | [0.2 d](/filings/0001628280-26-015637.md) | [0.1](/filings/0001628280-26-032875.md) | [0.1 d](/filings/0001628280-26-054840.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | period not labelled (2024-06-30) | period not labelled (2024-09-30) | period not labelled (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [7.6](/filings/0001611115-25-000017.md) | [7.8](/filings/0001628280-25-050622.md) | [8.2](/filings/0001628280-26-032875.md) | [22.0](/filings/0001628280-26-054840.md) | [57.7](/filings/0001628280-25-050622.md) | [58.9](/filings/0001628280-26-032875.md) | [63.9](/filings/0001628280-26-054840.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 61,216,703 at 2026-08-04, from the cover of the [10-Q filed 2026-08-07](/filings/0001628280-26-054840.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:44 ET. No prices; not investment advice.